nodes	percent_of_prediction	percent_of_DWPC	metapath
Salmeterol—CYP3A4—breast cancer	0.176	1	CbGaD
Salmeterol—CYP3A5—Lapatinib—breast cancer	0.0363	0.0649	CbGbCtD
Salmeterol—CYP2C8—Lapatinib—breast cancer	0.0349	0.0624	CbGbCtD
Salmeterol—CYP3A4—Exemestane—breast cancer	0.028	0.05	CbGbCtD
Salmeterol—CYP2C8—Raloxifene—breast cancer	0.0265	0.0473	CbGbCtD
Salmeterol—CYP3A7—Tamoxifen—breast cancer	0.0242	0.0433	CbGbCtD
Salmeterol—CYP3A7-CYP3A51P—Tamoxifen—breast cancer	0.0242	0.0433	CbGbCtD
Salmeterol—CYP3A4—Letrozole—breast cancer	0.0238	0.0425	CbGbCtD
Salmeterol—CYP3A4—Anastrozole—breast cancer	0.0212	0.0379	CbGbCtD
Salmeterol—CYP3A4—Toremifene—breast cancer	0.0194	0.0347	CbGbCtD
Salmeterol—CYP3A7—Paclitaxel—breast cancer	0.0189	0.0337	CbGbCtD
Salmeterol—CYP3A7-CYP3A51P—Paclitaxel—breast cancer	0.0189	0.0337	CbGbCtD
Salmeterol—CYP3A7-CYP3A51P—Irinotecan—breast cancer	0.0186	0.0333	CbGbCtD
Salmeterol—CYP3A7—Irinotecan—breast cancer	0.0186	0.0333	CbGbCtD
Salmeterol—CYP3A5—Tamoxifen—breast cancer	0.0182	0.0325	CbGbCtD
Salmeterol—CYP3A4—Fulvestrant—breast cancer	0.0181	0.0322	CbGbCtD
Salmeterol—CYP2C8—Tamoxifen—breast cancer	0.0175	0.0312	CbGbCtD
Salmeterol—CYP3A4—Thiotepa—breast cancer	0.0161	0.0287	CbGbCtD
Salmeterol—CYP3A4—Ixabepilone—breast cancer	0.0147	0.0263	CbGbCtD
Salmeterol—CYP3A4—Lapatinib—breast cancer	0.0142	0.0253	CbGbCtD
Salmeterol—CYP3A5—Paclitaxel—breast cancer	0.0142	0.0253	CbGbCtD
Salmeterol—CYP3A5—Irinotecan—breast cancer	0.014	0.0249	CbGbCtD
Salmeterol—CYP3A7-CYP3A51P—Docetaxel—breast cancer	0.0136	0.0244	CbGbCtD
Salmeterol—CYP3A7—Docetaxel—breast cancer	0.0136	0.0244	CbGbCtD
Salmeterol—CYP2C8—Paclitaxel—breast cancer	0.0136	0.0243	CbGbCtD
Salmeterol—CYP2C8—Fluorouracil—breast cancer	0.0129	0.023	CbGbCtD
Salmeterol—CYP3A4—Raloxifene—breast cancer	0.0107	0.0192	CbGbCtD
Salmeterol—CYP3A5—Docetaxel—breast cancer	0.0102	0.0183	CbGbCtD
Salmeterol—CYP3A4—Vinorelbine—breast cancer	0.00786	0.014	CbGbCtD
Salmeterol—CYP3A4—Tamoxifen—breast cancer	0.00709	0.0127	CbGbCtD
Salmeterol—CYP3A4—Mitoxantrone—breast cancer	0.00692	0.0124	CbGbCtD
Salmeterol—CYP3A4—Paclitaxel—breast cancer	0.00552	0.00986	CbGbCtD
Salmeterol—CYP3A4—Irinotecan—breast cancer	0.00545	0.00973	CbGbCtD
Salmeterol—CYP3A4—Vinblastine—breast cancer	0.00484	0.00865	CbGbCtD
Salmeterol—CYP3A4—Docetaxel—breast cancer	0.00399	0.00713	CbGbCtD
Salmeterol—CYP3A4—Doxorubicin—breast cancer	0.00298	0.00531	CbGbCtD
Salmeterol—Salbutamol—CYP3A4—breast cancer	0.000241	0.283	CrCbGaD
Salmeterol—Labetalol—CYP2D6—breast cancer	0.000205	0.241	CrCbGaD
Salmeterol—Propafenone—CYP2D6—breast cancer	0.000157	0.185	CrCbGaD
Salmeterol—Propafenone—CYP3A4—breast cancer	0.000135	0.158	CrCbGaD
Salmeterol—Propafenone—ABCB1—breast cancer	0.000112	0.132	CrCbGaD
Salmeterol—Nausea—Thiotepa—breast cancer	5.79e-05	0.000271	CcSEcCtD
Salmeterol—Infection—Docetaxel—breast cancer	5.78e-05	0.00027	CcSEcCtD
Salmeterol—Sinusitis—Epirubicin—breast cancer	5.78e-05	0.00027	CcSEcCtD
Salmeterol—Hyperglycaemia—Doxorubicin—breast cancer	5.76e-05	0.000269	CcSEcCtD
Salmeterol—Diarrhoea—Mitoxantrone—breast cancer	5.76e-05	0.000269	CcSEcCtD
Salmeterol—Diarrhoea—Irinotecan—breast cancer	5.76e-05	0.000269	CcSEcCtD
Salmeterol—Dry mouth—Capecitabine—breast cancer	5.75e-05	0.000269	CcSEcCtD
Salmeterol—Pneumonia—Doxorubicin—breast cancer	5.73e-05	0.000268	CcSEcCtD
Salmeterol—Nervous system disorder—Docetaxel—breast cancer	5.71e-05	0.000267	CcSEcCtD
Salmeterol—Infestation—Doxorubicin—breast cancer	5.7e-05	0.000266	CcSEcCtD
Salmeterol—Infestation NOS—Doxorubicin—breast cancer	5.7e-05	0.000266	CcSEcCtD
Salmeterol—Tachycardia—Docetaxel—breast cancer	5.68e-05	0.000265	CcSEcCtD
Salmeterol—Feeling abnormal—Paclitaxel—breast cancer	5.66e-05	0.000264	CcSEcCtD
Salmeterol—Skin disorder—Docetaxel—breast cancer	5.65e-05	0.000264	CcSEcCtD
Salmeterol—Oedema—Capecitabine—breast cancer	5.64e-05	0.000263	CcSEcCtD
Salmeterol—Gastrointestinal pain—Paclitaxel—breast cancer	5.62e-05	0.000262	CcSEcCtD
Salmeterol—Diarrhoea—Gemcitabine—breast cancer	5.61e-05	0.000262	CcSEcCtD
Salmeterol—Infection—Capecitabine—breast cancer	5.6e-05	0.000262	CcSEcCtD
Salmeterol—Dizziness—Irinotecan—breast cancer	5.57e-05	0.00026	CcSEcCtD
Salmeterol—Rhinitis—Epirubicin—breast cancer	5.54e-05	0.000259	CcSEcCtD
Salmeterol—Urinary tract infection—Doxorubicin—breast cancer	5.54e-05	0.000259	CcSEcCtD
Salmeterol—Conjunctivitis—Doxorubicin—breast cancer	5.54e-05	0.000259	CcSEcCtD
Salmeterol—Nervous system disorder—Capecitabine—breast cancer	5.53e-05	0.000258	CcSEcCtD
Salmeterol—Diarrhoea—Fluorouracil—breast cancer	5.52e-05	0.000258	CcSEcCtD
Salmeterol—Tachycardia—Capecitabine—breast cancer	5.5e-05	0.000257	CcSEcCtD
Salmeterol—Pharyngitis—Epirubicin—breast cancer	5.49e-05	0.000256	CcSEcCtD
Salmeterol—Cardiac disorder—Methotrexate—breast cancer	5.48e-05	0.000256	CcSEcCtD
Salmeterol—Skin disorder—Capecitabine—breast cancer	5.47e-05	0.000256	CcSEcCtD
Salmeterol—Urticaria—Paclitaxel—breast cancer	5.46e-05	0.000255	CcSEcCtD
Salmeterol—Connective tissue disorder—Epirubicin—breast cancer	5.43e-05	0.000254	CcSEcCtD
Salmeterol—Body temperature increased—Paclitaxel—breast cancer	5.43e-05	0.000254	CcSEcCtD
Salmeterol—Abdominal pain—Paclitaxel—breast cancer	5.43e-05	0.000254	CcSEcCtD
Salmeterol—Epistaxis—Doxorubicin—breast cancer	5.37e-05	0.000251	CcSEcCtD
Salmeterol—Vomiting—Mitoxantrone—breast cancer	5.35e-05	0.00025	CcSEcCtD
Salmeterol—Vomiting—Irinotecan—breast cancer	5.35e-05	0.00025	CcSEcCtD
Salmeterol—Sinusitis—Doxorubicin—breast cancer	5.34e-05	0.00025	CcSEcCtD
Salmeterol—Immune system disorder—Methotrexate—breast cancer	5.33e-05	0.000249	CcSEcCtD
Salmeterol—Dizziness—Fluorouracil—breast cancer	5.33e-05	0.000249	CcSEcCtD
Salmeterol—Mediastinal disorder—Methotrexate—breast cancer	5.32e-05	0.000249	CcSEcCtD
Salmeterol—Rash—Mitoxantrone—breast cancer	5.31e-05	0.000248	CcSEcCtD
Salmeterol—Rash—Irinotecan—breast cancer	5.31e-05	0.000248	CcSEcCtD
Salmeterol—Dermatitis—Mitoxantrone—breast cancer	5.3e-05	0.000248	CcSEcCtD
Salmeterol—Dermatitis—Irinotecan—breast cancer	5.3e-05	0.000248	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Docetaxel—breast cancer	5.3e-05	0.000248	CcSEcCtD
Salmeterol—Headache—Irinotecan—breast cancer	5.28e-05	0.000246	CcSEcCtD
Salmeterol—Headache—Mitoxantrone—breast cancer	5.28e-05	0.000246	CcSEcCtD
Salmeterol—Insomnia—Docetaxel—breast cancer	5.26e-05	0.000246	CcSEcCtD
Salmeterol—Paraesthesia—Docetaxel—breast cancer	5.23e-05	0.000244	CcSEcCtD
Salmeterol—Vomiting—Gemcitabine—breast cancer	5.22e-05	0.000244	CcSEcCtD
Salmeterol—Dyspnoea—Docetaxel—breast cancer	5.19e-05	0.000242	CcSEcCtD
Salmeterol—Mental disorder—Methotrexate—breast cancer	5.17e-05	0.000242	CcSEcCtD
Salmeterol—Rash—Gemcitabine—breast cancer	5.17e-05	0.000242	CcSEcCtD
Salmeterol—Dermatitis—Gemcitabine—breast cancer	5.17e-05	0.000241	CcSEcCtD
Salmeterol—Malnutrition—Methotrexate—breast cancer	5.14e-05	0.00024	CcSEcCtD
Salmeterol—Headache—Gemcitabine—breast cancer	5.14e-05	0.00024	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Capecitabine—breast cancer	5.13e-05	0.00024	CcSEcCtD
Salmeterol—Cardiac disorder—Epirubicin—breast cancer	5.13e-05	0.00024	CcSEcCtD
Salmeterol—Vomiting—Fluorouracil—breast cancer	5.13e-05	0.00024	CcSEcCtD
Salmeterol—Rhinitis—Doxorubicin—breast cancer	5.13e-05	0.000239	CcSEcCtD
Salmeterol—Dyspepsia—Docetaxel—breast cancer	5.12e-05	0.000239	CcSEcCtD
Salmeterol—Insomnia—Capecitabine—breast cancer	5.1e-05	0.000238	CcSEcCtD
Salmeterol—Rash—Fluorouracil—breast cancer	5.09e-05	0.000238	CcSEcCtD
Salmeterol—Dermatitis—Fluorouracil—breast cancer	5.08e-05	0.000237	CcSEcCtD
Salmeterol—Pharyngitis—Doxorubicin—breast cancer	5.08e-05	0.000237	CcSEcCtD
Salmeterol—Paraesthesia—Capecitabine—breast cancer	5.06e-05	0.000236	CcSEcCtD
Salmeterol—Hypersensitivity—Paclitaxel—breast cancer	5.06e-05	0.000236	CcSEcCtD
Salmeterol—Headache—Fluorouracil—breast cancer	5.05e-05	0.000236	CcSEcCtD
Salmeterol—Connective tissue disorder—Doxorubicin—breast cancer	5.02e-05	0.000235	CcSEcCtD
Salmeterol—Dyspnoea—Capecitabine—breast cancer	5.02e-05	0.000235	CcSEcCtD
Salmeterol—Fatigue—Docetaxel—breast cancer	5.02e-05	0.000234	CcSEcCtD
Salmeterol—Nausea—Mitoxantrone—breast cancer	5e-05	0.000234	CcSEcCtD
Salmeterol—Nausea—Irinotecan—breast cancer	5e-05	0.000234	CcSEcCtD
Salmeterol—Immune system disorder—Epirubicin—breast cancer	4.99e-05	0.000233	CcSEcCtD
Salmeterol—Mediastinal disorder—Epirubicin—breast cancer	4.98e-05	0.000233	CcSEcCtD
Salmeterol—Pain—Docetaxel—breast cancer	4.98e-05	0.000233	CcSEcCtD
Salmeterol—Constipation—Docetaxel—breast cancer	4.98e-05	0.000233	CcSEcCtD
Salmeterol—Back pain—Methotrexate—breast cancer	4.97e-05	0.000232	CcSEcCtD
Salmeterol—Dyspepsia—Capecitabine—breast cancer	4.96e-05	0.000232	CcSEcCtD
Salmeterol—Arrhythmia—Epirubicin—breast cancer	4.94e-05	0.000231	CcSEcCtD
Salmeterol—Asthenia—Paclitaxel—breast cancer	4.93e-05	0.00023	CcSEcCtD
Salmeterol—Nausea—Gemcitabine—breast cancer	4.87e-05	0.000228	CcSEcCtD
Salmeterol—Fatigue—Capecitabine—breast cancer	4.86e-05	0.000227	CcSEcCtD
Salmeterol—Mental disorder—Epirubicin—breast cancer	4.84e-05	0.000226	CcSEcCtD
Salmeterol—Pain—Capecitabine—breast cancer	4.82e-05	0.000225	CcSEcCtD
Salmeterol—Constipation—Capecitabine—breast cancer	4.82e-05	0.000225	CcSEcCtD
Salmeterol—Malnutrition—Epirubicin—breast cancer	4.81e-05	0.000225	CcSEcCtD
Salmeterol—Feeling abnormal—Docetaxel—breast cancer	4.8e-05	0.000224	CcSEcCtD
Salmeterol—Nausea—Fluorouracil—breast cancer	4.79e-05	0.000224	CcSEcCtD
Salmeterol—Ill-defined disorder—Methotrexate—breast cancer	4.77e-05	0.000223	CcSEcCtD
Salmeterol—Gastrointestinal pain—Docetaxel—breast cancer	4.76e-05	0.000222	CcSEcCtD
Salmeterol—Cardiac disorder—Doxorubicin—breast cancer	4.75e-05	0.000222	CcSEcCtD
Salmeterol—Tension—Epirubicin—breast cancer	4.72e-05	0.000221	CcSEcCtD
Salmeterol—Diarrhoea—Paclitaxel—breast cancer	4.7e-05	0.00022	CcSEcCtD
Salmeterol—Nervousness—Epirubicin—breast cancer	4.67e-05	0.000218	CcSEcCtD
Salmeterol—Back pain—Epirubicin—breast cancer	4.65e-05	0.000217	CcSEcCtD
Salmeterol—Feeling abnormal—Capecitabine—breast cancer	4.64e-05	0.000217	CcSEcCtD
Salmeterol—Malaise—Methotrexate—breast cancer	4.64e-05	0.000217	CcSEcCtD
Salmeterol—Muscle spasms—Epirubicin—breast cancer	4.63e-05	0.000216	CcSEcCtD
Salmeterol—Immune system disorder—Doxorubicin—breast cancer	4.62e-05	0.000216	CcSEcCtD
Salmeterol—Gastrointestinal pain—Capecitabine—breast cancer	4.61e-05	0.000215	CcSEcCtD
Salmeterol—Mediastinal disorder—Doxorubicin—breast cancer	4.61e-05	0.000215	CcSEcCtD
Salmeterol—Body temperature increased—Docetaxel—breast cancer	4.6e-05	0.000215	CcSEcCtD
Salmeterol—Abdominal pain—Docetaxel—breast cancer	4.6e-05	0.000215	CcSEcCtD
Salmeterol—Arrhythmia—Doxorubicin—breast cancer	4.57e-05	0.000213	CcSEcCtD
Salmeterol—Dizziness—Paclitaxel—breast cancer	4.54e-05	0.000212	CcSEcCtD
Salmeterol—Cough—Methotrexate—breast cancer	4.49e-05	0.00021	CcSEcCtD
Salmeterol—Mental disorder—Doxorubicin—breast cancer	4.48e-05	0.000209	CcSEcCtD
Salmeterol—Urticaria—Capecitabine—breast cancer	4.48e-05	0.000209	CcSEcCtD
Salmeterol—Ill-defined disorder—Epirubicin—breast cancer	4.46e-05	0.000209	CcSEcCtD
Salmeterol—Abdominal pain—Capecitabine—breast cancer	4.46e-05	0.000208	CcSEcCtD
Salmeterol—Body temperature increased—Capecitabine—breast cancer	4.46e-05	0.000208	CcSEcCtD
Salmeterol—Malnutrition—Doxorubicin—breast cancer	4.45e-05	0.000208	CcSEcCtD
Salmeterol—Agitation—Epirubicin—breast cancer	4.42e-05	0.000207	CcSEcCtD
Salmeterol—Myalgia—Methotrexate—breast cancer	4.38e-05	0.000204	CcSEcCtD
Salmeterol—Chest pain—Methotrexate—breast cancer	4.38e-05	0.000204	CcSEcCtD
Salmeterol—Arthralgia—Methotrexate—breast cancer	4.38e-05	0.000204	CcSEcCtD
Salmeterol—Tension—Doxorubicin—breast cancer	4.37e-05	0.000204	CcSEcCtD
Salmeterol—Vomiting—Paclitaxel—breast cancer	4.37e-05	0.000204	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	4.35e-05	0.000203	CcSEcCtD
Salmeterol—Malaise—Epirubicin—breast cancer	4.34e-05	0.000203	CcSEcCtD
Salmeterol—Rash—Paclitaxel—breast cancer	4.33e-05	0.000202	CcSEcCtD
Salmeterol—Dermatitis—Paclitaxel—breast cancer	4.33e-05	0.000202	CcSEcCtD
Salmeterol—Discomfort—Methotrexate—breast cancer	4.32e-05	0.000202	CcSEcCtD
Salmeterol—Nervousness—Doxorubicin—breast cancer	4.32e-05	0.000202	CcSEcCtD
Salmeterol—Back pain—Doxorubicin—breast cancer	4.31e-05	0.000201	CcSEcCtD
Salmeterol—Headache—Paclitaxel—breast cancer	4.3e-05	0.000201	CcSEcCtD
Salmeterol—Hypersensitivity—Docetaxel—breast cancer	4.29e-05	0.0002	CcSEcCtD
Salmeterol—Muscle spasms—Doxorubicin—breast cancer	4.28e-05	0.0002	CcSEcCtD
Salmeterol—Palpitations—Epirubicin—breast cancer	4.25e-05	0.000199	CcSEcCtD
Salmeterol—Cough—Epirubicin—breast cancer	4.2e-05	0.000196	CcSEcCtD
Salmeterol—Anaphylactic shock—Methotrexate—breast cancer	4.2e-05	0.000196	CcSEcCtD
Salmeterol—Asthenia—Docetaxel—breast cancer	4.18e-05	0.000195	CcSEcCtD
Salmeterol—Infection—Methotrexate—breast cancer	4.17e-05	0.000195	CcSEcCtD
Salmeterol—Hypertension—Epirubicin—breast cancer	4.15e-05	0.000194	CcSEcCtD
Salmeterol—Hypersensitivity—Capecitabine—breast cancer	4.15e-05	0.000194	CcSEcCtD
Salmeterol—Ill-defined disorder—Doxorubicin—breast cancer	4.13e-05	0.000193	CcSEcCtD
Salmeterol—Nervous system disorder—Methotrexate—breast cancer	4.11e-05	0.000192	CcSEcCtD
Salmeterol—Myalgia—Epirubicin—breast cancer	4.1e-05	0.000191	CcSEcCtD
Salmeterol—Chest pain—Epirubicin—breast cancer	4.1e-05	0.000191	CcSEcCtD
Salmeterol—Arthralgia—Epirubicin—breast cancer	4.1e-05	0.000191	CcSEcCtD
Salmeterol—Agitation—Doxorubicin—breast cancer	4.09e-05	0.000191	CcSEcCtD
Salmeterol—Anxiety—Epirubicin—breast cancer	4.08e-05	0.000191	CcSEcCtD
Salmeterol—Nausea—Paclitaxel—breast cancer	4.08e-05	0.000191	CcSEcCtD
Salmeterol—Skin disorder—Methotrexate—breast cancer	4.08e-05	0.00019	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	4.07e-05	0.00019	CcSEcCtD
Salmeterol—Discomfort—Epirubicin—breast cancer	4.05e-05	0.000189	CcSEcCtD
Salmeterol—Asthenia—Capecitabine—breast cancer	4.04e-05	0.000189	CcSEcCtD
Salmeterol—Malaise—Doxorubicin—breast cancer	4.01e-05	0.000188	CcSEcCtD
Salmeterol—Dry mouth—Epirubicin—breast cancer	4.01e-05	0.000187	CcSEcCtD
Salmeterol—Diarrhoea—Docetaxel—breast cancer	3.98e-05	0.000186	CcSEcCtD
Salmeterol—Palpitations—Doxorubicin—breast cancer	3.93e-05	0.000184	CcSEcCtD
Salmeterol—Anaphylactic shock—Epirubicin—breast cancer	3.93e-05	0.000183	CcSEcCtD
Salmeterol—Oedema—Epirubicin—breast cancer	3.93e-05	0.000183	CcSEcCtD
Salmeterol—Infection—Epirubicin—breast cancer	3.9e-05	0.000182	CcSEcCtD
Salmeterol—Cough—Doxorubicin—breast cancer	3.88e-05	0.000181	CcSEcCtD
Salmeterol—Diarrhoea—Capecitabine—breast cancer	3.86e-05	0.00018	CcSEcCtD
Salmeterol—Nervous system disorder—Epirubicin—breast cancer	3.85e-05	0.00018	CcSEcCtD
Salmeterol—Dizziness—Docetaxel—breast cancer	3.85e-05	0.00018	CcSEcCtD
Salmeterol—Hypertension—Doxorubicin—breast cancer	3.84e-05	0.00018	CcSEcCtD
Salmeterol—Tachycardia—Epirubicin—breast cancer	3.83e-05	0.000179	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Methotrexate—breast cancer	3.82e-05	0.000179	CcSEcCtD
Salmeterol—Skin disorder—Epirubicin—breast cancer	3.81e-05	0.000178	CcSEcCtD
Salmeterol—Insomnia—Methotrexate—breast cancer	3.79e-05	0.000177	CcSEcCtD
Salmeterol—Chest pain—Doxorubicin—breast cancer	3.79e-05	0.000177	CcSEcCtD
Salmeterol—Arthralgia—Doxorubicin—breast cancer	3.79e-05	0.000177	CcSEcCtD
Salmeterol—Myalgia—Doxorubicin—breast cancer	3.79e-05	0.000177	CcSEcCtD
Salmeterol—Anxiety—Doxorubicin—breast cancer	3.78e-05	0.000176	CcSEcCtD
Salmeterol—Paraesthesia—Methotrexate—breast cancer	3.77e-05	0.000176	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	3.76e-05	0.000176	CcSEcCtD
Salmeterol—Discomfort—Doxorubicin—breast cancer	3.74e-05	0.000175	CcSEcCtD
Salmeterol—Dyspnoea—Methotrexate—breast cancer	3.74e-05	0.000175	CcSEcCtD
Salmeterol—Dizziness—Capecitabine—breast cancer	3.73e-05	0.000174	CcSEcCtD
Salmeterol—Dry mouth—Doxorubicin—breast cancer	3.71e-05	0.000173	CcSEcCtD
Salmeterol—Vomiting—Docetaxel—breast cancer	3.7e-05	0.000173	CcSEcCtD
Salmeterol—Dyspepsia—Methotrexate—breast cancer	3.69e-05	0.000173	CcSEcCtD
Salmeterol—Rash—Docetaxel—breast cancer	3.67e-05	0.000171	CcSEcCtD
Salmeterol—Dermatitis—Docetaxel—breast cancer	3.67e-05	0.000171	CcSEcCtD
Salmeterol—Headache—Docetaxel—breast cancer	3.65e-05	0.00017	CcSEcCtD
Salmeterol—Oedema—Doxorubicin—breast cancer	3.63e-05	0.00017	CcSEcCtD
Salmeterol—Anaphylactic shock—Doxorubicin—breast cancer	3.63e-05	0.00017	CcSEcCtD
Salmeterol—Fatigue—Methotrexate—breast cancer	3.62e-05	0.000169	CcSEcCtD
Salmeterol—Infection—Doxorubicin—breast cancer	3.61e-05	0.000169	CcSEcCtD
Salmeterol—Pain—Methotrexate—breast cancer	3.59e-05	0.000168	CcSEcCtD
Salmeterol—Vomiting—Capecitabine—breast cancer	3.58e-05	0.000167	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Epirubicin—breast cancer	3.58e-05	0.000167	CcSEcCtD
Salmeterol—Nervous system disorder—Doxorubicin—breast cancer	3.56e-05	0.000166	CcSEcCtD
Salmeterol—Rash—Capecitabine—breast cancer	3.55e-05	0.000166	CcSEcCtD
Salmeterol—Insomnia—Epirubicin—breast cancer	3.55e-05	0.000166	CcSEcCtD
Salmeterol—Dermatitis—Capecitabine—breast cancer	3.55e-05	0.000166	CcSEcCtD
Salmeterol—Tachycardia—Doxorubicin—breast cancer	3.55e-05	0.000166	CcSEcCtD
Salmeterol—Headache—Capecitabine—breast cancer	3.53e-05	0.000165	CcSEcCtD
Salmeterol—Skin disorder—Doxorubicin—breast cancer	3.53e-05	0.000165	CcSEcCtD
Salmeterol—Paraesthesia—Epirubicin—breast cancer	3.53e-05	0.000165	CcSEcCtD
Salmeterol—Dyspnoea—Epirubicin—breast cancer	3.5e-05	0.000164	CcSEcCtD
Salmeterol—Nausea—Docetaxel—breast cancer	3.46e-05	0.000162	CcSEcCtD
Salmeterol—Feeling abnormal—Methotrexate—breast cancer	3.46e-05	0.000162	CcSEcCtD
Salmeterol—Dyspepsia—Epirubicin—breast cancer	3.46e-05	0.000161	CcSEcCtD
Salmeterol—Gastrointestinal pain—Methotrexate—breast cancer	3.43e-05	0.00016	CcSEcCtD
Salmeterol—Fatigue—Epirubicin—breast cancer	3.39e-05	0.000158	CcSEcCtD
Salmeterol—Pain—Epirubicin—breast cancer	3.36e-05	0.000157	CcSEcCtD
Salmeterol—Constipation—Epirubicin—breast cancer	3.36e-05	0.000157	CcSEcCtD
Salmeterol—Nausea—Capecitabine—breast cancer	3.35e-05	0.000156	CcSEcCtD
Salmeterol—Urticaria—Methotrexate—breast cancer	3.33e-05	0.000156	CcSEcCtD
Salmeterol—Abdominal pain—Methotrexate—breast cancer	3.32e-05	0.000155	CcSEcCtD
Salmeterol—Body temperature increased—Methotrexate—breast cancer	3.32e-05	0.000155	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Doxorubicin—breast cancer	3.31e-05	0.000155	CcSEcCtD
Salmeterol—Insomnia—Doxorubicin—breast cancer	3.29e-05	0.000154	CcSEcCtD
Salmeterol—Paraesthesia—Doxorubicin—breast cancer	3.26e-05	0.000152	CcSEcCtD
Salmeterol—Dyspnoea—Doxorubicin—breast cancer	3.24e-05	0.000151	CcSEcCtD
Salmeterol—Feeling abnormal—Epirubicin—breast cancer	3.24e-05	0.000151	CcSEcCtD
Salmeterol—Gastrointestinal pain—Epirubicin—breast cancer	3.21e-05	0.00015	CcSEcCtD
Salmeterol—Dyspepsia—Doxorubicin—breast cancer	3.2e-05	0.000149	CcSEcCtD
Salmeterol—Fatigue—Doxorubicin—breast cancer	3.13e-05	0.000146	CcSEcCtD
Salmeterol—Urticaria—Epirubicin—breast cancer	3.12e-05	0.000146	CcSEcCtD
Salmeterol—Constipation—Doxorubicin—breast cancer	3.11e-05	0.000145	CcSEcCtD
Salmeterol—Pain—Doxorubicin—breast cancer	3.11e-05	0.000145	CcSEcCtD
Salmeterol—Abdominal pain—Epirubicin—breast cancer	3.1e-05	0.000145	CcSEcCtD
Salmeterol—Body temperature increased—Epirubicin—breast cancer	3.1e-05	0.000145	CcSEcCtD
Salmeterol—Hypersensitivity—Methotrexate—breast cancer	3.09e-05	0.000144	CcSEcCtD
Salmeterol—Asthenia—Methotrexate—breast cancer	3.01e-05	0.000141	CcSEcCtD
Salmeterol—Feeling abnormal—Doxorubicin—breast cancer	2.99e-05	0.00014	CcSEcCtD
Salmeterol—Gastrointestinal pain—Doxorubicin—breast cancer	2.97e-05	0.000139	CcSEcCtD
Salmeterol—Hypersensitivity—Epirubicin—breast cancer	2.89e-05	0.000135	CcSEcCtD
Salmeterol—Urticaria—Doxorubicin—breast cancer	2.89e-05	0.000135	CcSEcCtD
Salmeterol—Body temperature increased—Doxorubicin—breast cancer	2.87e-05	0.000134	CcSEcCtD
Salmeterol—Abdominal pain—Doxorubicin—breast cancer	2.87e-05	0.000134	CcSEcCtD
Salmeterol—Diarrhoea—Methotrexate—breast cancer	2.87e-05	0.000134	CcSEcCtD
Salmeterol—Asthenia—Epirubicin—breast cancer	2.82e-05	0.000132	CcSEcCtD
Salmeterol—Dizziness—Methotrexate—breast cancer	2.77e-05	0.00013	CcSEcCtD
Salmeterol—Diarrhoea—Epirubicin—breast cancer	2.69e-05	0.000126	CcSEcCtD
Salmeterol—Hypersensitivity—Doxorubicin—breast cancer	2.68e-05	0.000125	CcSEcCtD
Salmeterol—Vomiting—Methotrexate—breast cancer	2.67e-05	0.000125	CcSEcCtD
Salmeterol—Rash—Methotrexate—breast cancer	2.65e-05	0.000124	CcSEcCtD
Salmeterol—Dermatitis—Methotrexate—breast cancer	2.64e-05	0.000123	CcSEcCtD
Salmeterol—Headache—Methotrexate—breast cancer	2.63e-05	0.000123	CcSEcCtD
Salmeterol—Asthenia—Doxorubicin—breast cancer	2.61e-05	0.000122	CcSEcCtD
Salmeterol—Dizziness—Epirubicin—breast cancer	2.6e-05	0.000121	CcSEcCtD
Salmeterol—Vomiting—Epirubicin—breast cancer	2.5e-05	0.000117	CcSEcCtD
Salmeterol—Nausea—Methotrexate—breast cancer	2.49e-05	0.000116	CcSEcCtD
Salmeterol—Diarrhoea—Doxorubicin—breast cancer	2.49e-05	0.000116	CcSEcCtD
Salmeterol—Rash—Epirubicin—breast cancer	2.48e-05	0.000116	CcSEcCtD
Salmeterol—Dermatitis—Epirubicin—breast cancer	2.47e-05	0.000116	CcSEcCtD
Salmeterol—Headache—Epirubicin—breast cancer	2.46e-05	0.000115	CcSEcCtD
Salmeterol—Dizziness—Doxorubicin—breast cancer	2.4e-05	0.000112	CcSEcCtD
Salmeterol—Nausea—Epirubicin—breast cancer	2.33e-05	0.000109	CcSEcCtD
Salmeterol—Vomiting—Doxorubicin—breast cancer	2.31e-05	0.000108	CcSEcCtD
Salmeterol—Rash—Doxorubicin—breast cancer	2.29e-05	0.000107	CcSEcCtD
Salmeterol—Dermatitis—Doxorubicin—breast cancer	2.29e-05	0.000107	CcSEcCtD
Salmeterol—Headache—Doxorubicin—breast cancer	2.28e-05	0.000106	CcSEcCtD
Salmeterol—Nausea—Doxorubicin—breast cancer	2.16e-05	0.000101	CcSEcCtD
Salmeterol—ADRB2—Signaling by GPCR—PIK3CD—breast cancer	7.96e-06	0.00016	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CYP1A1—breast cancer	7.95e-06	0.00016	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PDGFA—breast cancer	7.95e-06	0.00016	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—SLC2A1—breast cancer	7.91e-06	0.000159	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NQO1—breast cancer	7.91e-06	0.000159	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HADHB—breast cancer	7.89e-06	0.000159	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GPI—breast cancer	7.89e-06	0.000159	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ERCC2—breast cancer	7.89e-06	0.000159	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TGFBR2—breast cancer	7.83e-06	0.000158	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP17A1—breast cancer	7.81e-06	0.000157	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PTGS1—breast cancer	7.73e-06	0.000155	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ENO1—breast cancer	7.73e-06	0.000155	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP3A4—breast cancer	7.72e-06	0.000155	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ITPR1—breast cancer	7.71e-06	0.000155	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	7.7e-06	0.000155	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MMP3—breast cancer	7.66e-06	0.000154	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ERBB4—breast cancer	7.66e-06	0.000154	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—STAT5A—breast cancer	7.66e-06	0.000154	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—PIK3CB—breast cancer	7.64e-06	0.000154	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—ALB—breast cancer	7.6e-06	0.000153	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP1B1—breast cancer	7.59e-06	0.000153	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP2D6—breast cancer	7.58e-06	0.000152	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ALDH7A1—breast cancer	7.53e-06	0.000152	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ALDH1A1—breast cancer	7.53e-06	0.000152	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—HSP90AA1—breast cancer	7.44e-06	0.00015	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NCOA2—breast cancer	7.44e-06	0.00015	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SMAD4—breast cancer	7.42e-06	0.000149	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—MTHFR—breast cancer	7.41e-06	0.000149	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IGF1R—breast cancer	7.37e-06	0.000148	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—CXCL8—breast cancer	7.34e-06	0.000148	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HES1—breast cancer	7.24e-06	0.000146	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NCOA1—breast cancer	7.24e-06	0.000146	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—FHL2—breast cancer	7.22e-06	0.000145	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ADSL—breast cancer	7.22e-06	0.000145	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NME1—breast cancer	7.22e-06	0.000145	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—UMPS—breast cancer	7.22e-06	0.000145	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PHGDH—breast cancer	7.22e-06	0.000145	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—FASN—breast cancer	7.21e-06	0.000145	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NCOR1—breast cancer	7.2e-06	0.000145	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PLA2G4A—breast cancer	7.2e-06	0.000145	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—BCHE—breast cancer	7.18e-06	0.000145	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP19A1—breast cancer	7.13e-06	0.000144	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—STK11—breast cancer	7.13e-06	0.000144	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CSF2—breast cancer	7.12e-06	0.000143	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FGF1—breast cancer	7.12e-06	0.000143	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—RAF1—breast cancer	7.1e-06	0.000143	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—SLC5A5—breast cancer	7.1e-06	0.000143	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—BRIP1—breast cancer	7.08e-06	0.000142	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—LDHB—breast cancer	7.08e-06	0.000142	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HPSE—breast cancer	7.08e-06	0.000142	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NRG1—breast cancer	7.07e-06	0.000142	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—H2AFX—breast cancer	7.02e-06	0.000141	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—IL2—breast cancer	7.01e-06	0.000141	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—E2F1—breast cancer	6.97e-06	0.00014	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PIK3CB—breast cancer	6.93e-06	0.00014	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—SLC2A1—breast cancer	6.85e-06	0.000138	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NQO1—breast cancer	6.85e-06	0.000138	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CAV1—breast cancer	6.84e-06	0.000138	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTA3—breast cancer	6.71e-06	0.000135	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ABCC1—breast cancer	6.71e-06	0.000135	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HMMR—breast cancer	6.71e-06	0.000135	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	6.71e-06	0.000135	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SPP1—breast cancer	6.69e-06	0.000135	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP3A4—breast cancer	6.68e-06	0.000134	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—CXCL8—breast cancer	6.66e-06	0.000134	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	6.65e-06	0.000134	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—COMT—breast cancer	6.63e-06	0.000133	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ERBB3—breast cancer	6.62e-06	0.000133	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FGFR2—breast cancer	6.61e-06	0.000133	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GSTP1—breast cancer	6.6e-06	0.000133	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP1B1—breast cancer	6.57e-06	0.000132	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—HMOX1—breast cancer	6.51e-06	0.000131	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PPARGC1B—breast cancer	6.5e-06	0.000131	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ITPR1—breast cancer	6.49e-06	0.000131	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—HSP90AA1—breast cancer	6.44e-06	0.00013	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—IL2—breast cancer	6.37e-06	0.000128	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TERT—breast cancer	6.35e-06	0.000128	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NCOA1—breast cancer	6.27e-06	0.000126	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ABCB1—breast cancer	6.25e-06	0.000126	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PIK3CG—breast cancer	6.23e-06	0.000125	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—STK11—breast cancer	6.18e-06	0.000124	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP19A1—breast cancer	6.18e-06	0.000124	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FGFR1—breast cancer	6.16e-06	0.000124	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CA9—breast cancer	6.14e-06	0.000124	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTA4—breast cancer	6.14e-06	0.000124	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—TYMS—breast cancer	6.13e-06	0.000123	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HIF1A—breast cancer	6.07e-06	0.000122	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NCOR1—breast cancer	6.06e-06	0.000122	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PLA2G4A—breast cancer	6.06e-06	0.000122	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GSTM1—breast cancer	6.06e-06	0.000122	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTA2—breast cancer	5.98e-06	0.00012	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GPX2—breast cancer	5.98e-06	0.00012	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—LEP—breast cancer	5.92e-06	0.000119	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GPX4—breast cancer	5.91e-06	0.000119	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SULT1A1—breast cancer	5.91e-06	0.000119	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CAV1—breast cancer	5.87e-06	0.000118	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GPX1—breast cancer	5.81e-06	0.000117	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—KDR—breast cancer	5.8e-06	0.000117	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—breast cancer	5.8e-06	0.000117	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—IDH1—breast cancer	5.77e-06	0.000116	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTA1—breast cancer	5.77e-06	0.000116	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP1A1—breast cancer	5.75e-06	0.000116	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—COMT—breast cancer	5.74e-06	0.000116	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTP1—breast cancer	5.72e-06	0.000115	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NAT2—breast cancer	5.71e-06	0.000115	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ERCC2—breast cancer	5.7e-06	0.000115	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ESR1—breast cancer	5.66e-06	0.000114	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—HMOX1—breast cancer	5.64e-06	0.000113	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ITPR1—breast cancer	5.62e-06	0.000113	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FN1—breast cancer	5.59e-06	0.000112	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NFKBIA—breast cancer	5.52e-06	0.000111	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PIK3CD—breast cancer	5.48e-06	0.00011	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NOTCH1—breast cancer	5.47e-06	0.00011	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ABCB1—breast cancer	5.41e-06	0.000109	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ALB—breast cancer	5.41e-06	0.000109	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—MTHFR—breast cancer	5.36e-06	0.000108	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—APC—breast cancer	5.35e-06	0.000108	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PIK3CG—breast cancer	5.35e-06	0.000108	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—KIT—breast cancer	5.35e-06	0.000108	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—TYMS—breast cancer	5.31e-06	0.000107	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—EGF—breast cancer	5.28e-06	0.000106	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PLA2G4A—breast cancer	5.25e-06	0.000106	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTM1—breast cancer	5.25e-06	0.000106	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NCOR1—breast cancer	5.25e-06	0.000106	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—NOS3—breast cancer	5.17e-06	0.000104	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—MAPK3—breast cancer	5.12e-06	0.000103	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GPX1—breast cancer	5.03e-06	0.000101	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—BRAF—breast cancer	5.02e-06	0.000101	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—MED12—breast cancer	5.01e-06	0.000101	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—DPYD—breast cancer	5.01e-06	0.000101	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP1A1—breast cancer	4.98e-06	0.0001	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CAV1—breast cancer	4.94e-06	9.95e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ERCC2—breast cancer	4.94e-06	9.94e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ALDOA—breast cancer	4.93e-06	9.91e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IGF1—breast cancer	4.89e-06	9.85e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—AKT2—breast cancer	4.89e-06	9.84e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—EGFR—breast cancer	4.87e-06	9.8e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NCOA3—breast cancer	4.78e-06	9.63e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PIK3CB—breast cancer	4.77e-06	9.6e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SLC2A2—breast cancer	4.75e-06	9.56e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PTGS2—breast cancer	4.73e-06	9.52e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PIK3CD—breast cancer	4.7e-06	9.46e-05	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—PIK3CA—breast cancer	4.65e-06	9.37e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—MTR—breast cancer	4.65e-06	9.36e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CPT1A—breast cancer	4.65e-06	9.36e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ABCG2—breast cancer	4.65e-06	9.36e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SERPINE1—breast cancer	4.65e-06	9.35e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—MTHFR—breast cancer	4.64e-06	9.34e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—KRAS—breast cancer	4.6e-06	9.26e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HPGDS—breast cancer	4.56e-06	9.18e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HBA1—breast cancer	4.53e-06	9.12e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PIK3CG—breast cancer	4.5e-06	9.06e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NOS3—breast cancer	4.44e-06	8.93e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTT1—breast cancer	4.43e-06	8.91e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ACHE—breast cancer	4.43e-06	8.91e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CAV1—breast cancer	4.28e-06	8.62e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PIK3CA—breast cancer	4.23e-06	8.51e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MDM2—breast cancer	4.21e-06	8.47e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—RAF1—breast cancer	4.2e-06	8.44e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP17A1—breast cancer	4.19e-06	8.43e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—RELA—breast cancer	4.18e-06	8.41e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ERBB2—breast cancer	4.15e-06	8.35e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ENO1—breast cancer	4.15e-06	8.35e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PTGS1—breast cancer	4.15e-06	8.35e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PTEN—breast cancer	4.12e-06	8.3e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MTOR—breast cancer	4.1e-06	8.24e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PIK3CB—breast cancer	4.1e-06	8.24e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	4.09e-06	8.23e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP2D6—breast cancer	4.07e-06	8.18e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NCOA2—breast cancer	3.99e-06	8.03e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PIK3CD—breast cancer	3.96e-06	7.97e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CXCL8—breast cancer	3.94e-06	7.92e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—HRAS—breast cancer	3.91e-06	7.87e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ALB—breast cancer	3.91e-06	7.86e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PIK3CG—breast cancer	3.9e-06	7.85e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—FASN—breast cancer	3.87e-06	7.79e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—BCHE—breast cancer	3.86e-06	7.76e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CDKN1B—breast cancer	3.84e-06	7.74e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SLC5A5—breast cancer	3.81e-06	7.66e-05	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—AKT1—breast cancer	3.8e-06	7.65e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CASP3—breast cancer	3.77e-06	7.58e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IL2—breast cancer	3.76e-06	7.57e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—IL6—breast cancer	3.74e-06	7.53e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NOS3—breast cancer	3.74e-06	7.52e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SLC2A1—breast cancer	3.68e-06	7.4e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NQO1—breast cancer	3.68e-06	7.4e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CCND1—breast cancer	3.67e-06	7.38e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—JUN—breast cancer	3.66e-06	7.36e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CTNNB1—breast cancer	3.63e-06	7.31e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MMP9—breast cancer	3.56e-06	7.16e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CDKN1A—breast cancer	3.55e-06	7.14e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PTEN—breast cancer	3.54e-06	7.12e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP1B1—breast cancer	3.53e-06	7.1e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MAPK8—breast cancer	3.46e-06	6.97e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HSP90AA1—breast cancer	3.46e-06	6.96e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—AKT1—breast cancer	3.45e-06	6.95e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PIK3CB—breast cancer	3.45e-06	6.94e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PIK3CD—breast cancer	3.43e-06	6.9e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PTGS2—breast cancer	3.42e-06	6.88e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ALB—breast cancer	3.38e-06	6.81e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NCOA1—breast cancer	3.36e-06	6.77e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—STK11—breast cancer	3.32e-06	6.67e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP19A1—breast cancer	3.32e-06	6.67e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SRC—breast cancer	3.28e-06	6.61e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NOS3—breast cancer	3.24e-06	6.51e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—VEGFA—breast cancer	3.2e-06	6.43e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—STAT3—breast cancer	3.17e-06	6.37e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—COMT—breast cancer	3.08e-06	6.2e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTP1—breast cancer	3.07e-06	6.17e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HMOX1—breast cancer	3.03e-06	6.09e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MAPK3—breast cancer	3.02e-06	6.09e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ITPR1—breast cancer	3.02e-06	6.07e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PIK3CB—breast cancer	2.99e-06	6.01e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PTEN—breast cancer	2.98e-06	6e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PTGS2—breast cancer	2.96e-06	5.96e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MYC—breast cancer	2.94e-06	5.92e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TGFB1—breast cancer	2.93e-06	5.91e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PIK3CA—breast cancer	2.91e-06	5.85e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ABCB1—breast cancer	2.9e-06	5.84e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—EGFR—breast cancer	2.88e-06	5.79e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—TYMS—breast cancer	2.85e-06	5.74e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NCOR1—breast cancer	2.82e-06	5.67e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PLA2G4A—breast cancer	2.82e-06	5.67e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTM1—breast cancer	2.82e-06	5.67e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—KRAS—breast cancer	2.72e-06	5.47e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GPX1—breast cancer	2.7e-06	5.43e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP1A1—breast cancer	2.67e-06	5.38e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ERCC2—breast cancer	2.65e-06	5.33e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PTEN—breast cancer	2.58e-06	5.2e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PIK3CA—breast cancer	2.5e-06	5.02e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—MTHFR—breast cancer	2.49e-06	5.01e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TP53—breast cancer	2.42e-06	4.86e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—AKT1—breast cancer	2.38e-06	4.78e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HRAS—breast cancer	2.31e-06	4.65e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CAV1—breast cancer	2.3e-06	4.62e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IL6—breast cancer	2.21e-06	4.45e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PIK3CA—breast cancer	2.1e-06	4.23e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PIK3CG—breast cancer	2.09e-06	4.21e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—AKT1—breast cancer	2.04e-06	4.1e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PIK3CD—breast cancer	1.84e-06	3.7e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PIK3CA—breast cancer	1.82e-06	3.67e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ALB—breast cancer	1.82e-06	3.66e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NOS3—breast cancer	1.74e-06	3.5e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—AKT1—breast cancer	1.72e-06	3.46e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PIK3CB—breast cancer	1.6e-06	3.23e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PTGS2—breast cancer	1.59e-06	3.2e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—AKT1—breast cancer	1.49e-06	2.99e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PTEN—breast cancer	1.39e-06	2.79e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PIK3CA—breast cancer	9.78e-07	1.97e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—AKT1—breast cancer	7.99e-07	1.61e-05	CbGpPWpGaD
